A COST-EFFECTIVENESS STUDY OF SECOND-LINE TREATMENT IN PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER IN SPAIN

被引：0
|
作者：
Arlandis, S.
Castro, D.
Errando, C.
Fernandez, E.
Jimenez, M.
Gonzalez, P.
Crespo, C.
Stauble, F.
Rodriguez, J. M.
机构：
[1] Hosp Univ La Fe, Valencia, Spain
[2] Hosp Clin, Santa Cruz De Tenerife, Spain
[3] Fundacio Puigvert, Barcelona, Spain
[4] Hosp Ramon & Cajal, E-28034 Madrid, Spain
[5] Medtron Iber SA, Madrid, Spain
[6] Oblikue Consulting, Barcelona, Spain
[7] Medtron Int Trading Sarl, Suiza, Spain
来源：
GACETA SANITARIA | 2009年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：200 / 201
页数：2
相关论文
共 50 条
  • [11] Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain
    Villa, G.
    Hernandez-Pastor, L. J.
    Guix, M.
    Lavernia, J.
    Cuesta, M.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (01): : 24 - 33
  • [12] Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain
    G. Villa
    L. J. Hernández-Pastor
    M. Guix
    J. Lavernia
    M. Cuesta
    [J]. Clinical and Translational Oncology, 2015, 17 : 24 - 33
  • [13] A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder
    Jonathan P. Shepherd
    Charelle M. Carter-Brooks
    Christopher Chermanksy
    [J]. International Urogynecology Journal, 2018, 29 : 1213 - 1219
  • [14] A Cost-Effectiveness Analysis of Onabotulinumtoxin A as First-Line Treatment for Overactive Bladder
    不详
    [J]. OBSTETRICAL & GYNECOLOGICAL SURVEY, 2018, 73 (11) : 629 - 630
  • [15] A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder
    Shepherd, Jonathan P.
    Carter-Brooks, Charelle M.
    Chermanksy, Christopher
    [J]. INTERNATIONAL UROGYNECOLOGY JOURNAL, 2018, 29 (08) : 1213 - 1219
  • [16] COST-EFFECTIVENESS OF PEMBROLIZUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED UROTHELIAL CANCER IN FRANCE
    Robert, J.
    Culine, S.
    Roupret, M.
    Zhong, Y.
    Prabhu, V. S.
    Xu, R.
    Li, H.
    Lafuma, A.
    Bensimon, L.
    Clement, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S44 - S44
  • [17] Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model
    Arlandis-Guzman, Salvador
    Errando-Smet, Carlos
    Trocio, Jeffrey
    Arumi, Daniel
    Rejas, Javier
    [J]. BMC UROLOGY, 2011, 11
  • [18] Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model
    Salvador Arlandis-Guzman
    Carlos Errando-Smet
    Jeffrey Trocio
    Daniel Arumi
    Javier Rejas
    [J]. BMC Urology, 11
  • [19] COST-EFFECTIVENESS OF SACRAL NEUROMODULATION IN THE TREATMENT OF IDIOPATHIC WET REFRACTORY OVERACTIVE BLADDER IN ITALY
    D'Ausilio, A.
    Bertapelle, P.
    Vottero, M.
    Del Popolo, G.
    Giannantoni, A.
    Ostardo, E.
    Spinelli, M.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A357 - A357
  • [20] Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
    Soto-Perez-de-Celis, Enrique
    Aguiar, Pedro N., Jr.
    Cordon, Monica L.
    Chavarri-Guerra, Yanin
    Lopes, Gilberto de Lima, Jr.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (06): : 669 - 675
12345